---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-25-000103"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:26:42.721361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint

## Summary
- Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.
- Second pivotal Phase 3 (COMP006) enrolling well; 26-week data expected H2 2026.
- Exploring accelerated filing pathway for COMP360 in TRD; DSMB found no safety concerns in Phase 3 studies.
- Net loss $38.4M (Q2 2025) vs $38.1M (Q2 2024); net loss per share $0.41 vs $0.56.
- Cash $221.9M at June 30, 2025; cash runway into 2027; FY2025 net cash used in ops guidance $120-145M.

## SEC filing metadata
- accession: 0001816590-25-000103
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/0001816590-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/cmps-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-25-000103
- JSON: https://secwatch.observer/filing/0001816590-25-000103.json
- Plain text: https://secwatch.observer/filing/0001816590-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.